- Home
- ALRN vs OMGA Comparison
ALRN vs OMGA Comparison
Compare ALRN & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRN
- OMGA
- Stock Information
- Founded
- ALRN 2001
- OMGA 2017
- Country
- ALRN United States
- OMGA United States
- Employees
- ALRN N/A
- OMGA N/A
- Industry
- ALRN Biotechnology: Pharmaceutical Preparations
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- ALRN Health Care
- OMGA Health Care
- Exchange
- ALRN Nasdaq
- OMGA Nasdaq
- Market Cap
- ALRN 76.9M
- OMGA 74.5M
- IPO Year
- ALRN 2017
- OMGA 2021
- Fundamental
- Price
- ALRN $3.42
- OMGA $1.01
- Analyst Decision
- ALRN Strong Buy
- OMGA Strong Buy
- Analyst Count
- ALRN 1
- OMGA 5
- Target Price
- ALRN $19.00
- OMGA $10.20
- AVG Volume (30 Days)
- ALRN 93.8K
- OMGA 399.1K
- Earning Date
- ALRN 11-26-2024
- OMGA 11-19-2024
- Dividend Yield
- ALRN N/A
- OMGA N/A
- EPS Growth
- ALRN N/A
- OMGA N/A
- EPS
- ALRN N/A
- OMGA N/A
- Revenue
- ALRN N/A
- OMGA $6,314,000.00
- Revenue This Year
- ALRN N/A
- OMGA $127.25
- Revenue Next Year
- ALRN N/A
- OMGA N/A
- P/E Ratio
- ALRN N/A
- OMGA N/A
- Revenue Growth
- ALRN N/A
- OMGA 142.47
- 52 Week Low
- ALRN $1.57
- OMGA $0.89
- 52 Week High
- ALRN $7.42
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- ALRN 47.41
- OMGA 40.48
- Support Level
- ALRN $3.37
- OMGA $1.06
- Resistance Level
- ALRN $3.92
- OMGA $1.17
- Average True Range (ATR)
- ALRN 0.35
- OMGA 0.11
- MACD
- ALRN -0.06
- OMGA -0.01
- Stochastic Oscillator
- ALRN 21.36
- OMGA 2.44
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.